Teleflex (TFX) said Wednesday that the US Food and Drug Administration gave 501(k) clearance for expanded use of the QuikClot Control+ hemostatic device to include all grades of internal and external bleeding.
The expanded clearance covers procedures in general surgery, gynecologic surgery, orthopedic surgery and other areas, the company added.
The expanded use will add more than $150 million to the company's serviceable addressable market in the US, according to Teleflex.
Shares of the company were down 3% in recent trading.
Price: 134.33, Change: -3.89, Percent Change: -2.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.